Delayed
Nasdaq
18:13:43 08/05/2024 BST
|
5-day change
|
1st Jan Change
|
2.66
USD
|
+1.92%
|
|
+11.30%
|
-62.85%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
297.7
|
365.6
|
111.8
|
24.35
|
95.38
|
33.9
|
-
|
-
|
Enterprise Value (EV)
1 |
243.5
|
299.3
|
111.8
|
24.35
|
95.38
|
33.9
|
33.9
|
33.9
|
P/E ratio
|
-6.44
x
|
-6.7
x
|
-2.96
x
|
-0.59
x
|
-3.54
x
|
-
|
7.68
x
|
3.78
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
72.1
x
|
24.1
x
|
3.71
x
|
0.56
x
|
2.82
x
|
0.57
x
|
0.38
x
|
0.29
x
|
EV / Revenue
|
72.1
x
|
24.1
x
|
3.71
x
|
0.56
x
|
2.82
x
|
0.57
x
|
0.38
x
|
0.29
x
|
EV / EBITDA
|
-9,234,771
x
|
-11,520,029
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-3,125,101
x
|
-912,171
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
9,635
|
12,394
|
13,980
|
13,606
|
13,322
|
12,989
|
-
|
-
|
Reference price
2 |
30.90
|
29.50
|
8.000
|
1.790
|
7.160
|
2.610
|
2.610
|
2.610
|
Announcement Date
|
16/03/20
|
30/03/21
|
28/03/22
|
26/04/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.131
|
15.14
|
30.17
|
43.11
|
33.88
|
59.17
|
88.09
|
118
|
EBITDA
|
-32.24
|
-31.74
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-39.99
|
-33.7
|
-41.84
|
-34.03
|
-25.08
|
0.049
|
14.84
|
30.61
|
Operating Margin
|
-968.07%
|
-222.56%
|
-138.68%
|
-78.95%
|
-74.03%
|
0.08%
|
16.85%
|
25.93%
|
Earnings before Tax (EBT)
1 |
-45.36
|
-47.51
|
-35.84
|
-37.43
|
-26.29
|
0.049
|
14.84
|
30.61
|
Net income
1 |
-46.03
|
-48.29
|
-36.65
|
-41.01
|
-26.96
|
0.037
|
11.13
|
22.96
|
Net margin
|
-1,114.31%
|
-318.92%
|
-121.5%
|
-95.14%
|
-79.58%
|
0.06%
|
12.63%
|
19.45%
|
EPS
2 |
-4.800
|
-4.400
|
-2.700
|
-3.010
|
-2.020
|
-
|
0.3400
|
0.6900
|
Free Cash Flow
|
-
|
-
|
-35.79
|
-26.7
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-118.63%
|
-61.94%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
30/03/21
|
28/03/22
|
26/04/23
|
28/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
8.112
|
9.158
|
9.062
|
8.573
|
10.21
|
15.26
|
8.347
|
9.82
|
8.838
|
6.874
|
12
|
13.8
|
15.5
|
17.8
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
|
-6.892
|
-11.44
|
-7.29
|
-7.746
|
-6.354
|
-12.64
|
-
|
-9.345
|
-5.095
|
-3.427
|
-
|
-
|
-
|
-
|
Operating Margin
|
-84.96%
|
-124.86%
|
-80.45%
|
-90.35%
|
-62.21%
|
-82.85%
|
-
|
-95.16%
|
-57.65%
|
-49.85%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-10.02
|
-4.789
|
-8.4
|
-7.493
|
-5.023
|
-16.52
|
-
|
-10.06
|
-4.451
|
-5.972
|
-
|
-
|
-
|
-
|
Net income
|
-10.22
|
-5.601
|
-8.596
|
-7.68
|
-5.201
|
-19.54
|
-
|
-10.24
|
-4.635
|
-6.077
|
-
|
-
|
-
|
-
|
Net margin
|
-126.04%
|
-61.16%
|
-94.86%
|
-89.58%
|
-50.93%
|
-128.04%
|
-
|
-104.27%
|
-52.44%
|
-88.41%
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7000
|
-0.4000
|
-0.6000
|
-0.5600
|
-0.3800
|
-1.440
|
-0.4500
|
-0.7700
|
-0.3500
|
-0.4600
|
-0.0500
|
-0.0100
|
0.0100
|
0.0300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/21
|
28/03/22
|
12/05/22
|
12/08/22
|
14/11/22
|
26/04/23
|
17/05/23
|
11/08/23
|
14/11/23
|
28/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
54.2
|
66.4
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-35.8
|
-26.7
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.43
|
1.5
|
8.95
|
5.61
|
-
|
-
|
-
|
-
|
Capex / Sales
|
10.34%
|
9.9%
|
29.65%
|
13.02%
|
-
|
-
|
-
|
-
|
Announcement Date
|
16/03/20
|
30/03/21
|
28/03/22
|
26/04/23
|
28/03/24
|
-
|
-
|
-
|
Last Close Price
2.61
USD Average target price
12
USD Spread / Average Target +359.77% Consensus |
1st Jan change
|
Capi.
|
---|
| -62.85% | 33.9M | | +33.13% | 700B | | -4.98% | 358B | | +18.93% | 330B | | +3.35% | 287B | | +15.70% | 236B | | +6.68% | 202B | | -9.08% | 197B | | +6.06% | 161B | | -1.94% | 157B |
Other Pharmaceuticals
|